Last reviewed · How we verify
Hydrocortisone Modified Release Capsules
Glucocorticoid receptor agonist
Glucocorticoid receptor agonist Used for Eczema, Psoriasis, Rheumatoid arthritis.
At a glance
| Generic name | Hydrocortisone Modified Release Capsules |
|---|---|
| Also known as | Chronocort |
| Sponsor | Neurocrine UK Limited |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Hydrocortisone modified release capsules work by activating the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects.
Approved indications
- Eczema
- Psoriasis
- Rheumatoid arthritis
Common side effects
- Hypertension
- Hyperglycemia
- Headache
Key clinical trials
- Long-term Safety Study of Chronocort in the Treatment of Participants With Congenital Adrenal Hyperplasia (PHASE3)
- Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia (PHASE3)
- Chronocort Versus Plenadren Replacement Therapy in Adults With Adrenal Insufficiency (PHASE2)
- Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (PHASE3)
- Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia (PHASE3)
- Pilot Study to Characterize and Examine the Pharmacokinetics and Efficacy of Chronocort® in Adults With CAH (PHASE2)
- An Open Label Study in Healthy Volunteers to Compare Chronocort® to Hydrocortisone (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: